Silence Therapeutics plc
SLNCF
$1.69
$0.0855.31%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -61.44% | -69.01% | 12.09% | -43.58% | -0.10% |
| Total Depreciation and Amortization | -2.60% | -1.89% | -1.31% | -6.59% | -1.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.01% | -39.27% | -78.52% | -1.78% | -31.85% |
| Change in Net Operating Assets | -687.60% | 71.00% | -73.67% | 96.93% | 116.05% |
| Cash from Operations | -148.17% | -46.26% | -39.29% | -9.31% | 35.86% |
| Capital Expenditure | -64.64% | -916.74% | -295.21% | -157.44% | -25.63% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 15.67% | 36.98% | -229.35% | -7,731.59% | 0.43% |
| Cash from Investing | 15.32% | 36.31% | -230.83% | -8,146.24% | 0.34% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 13.49% | 59.48% | 272.70% | 156.41% | 167.37% |
| Issuance of Common Stock | -95.99% | -95.30% | 410.26% | 840.70% | 240.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 4,370.56% | 4,370.56% | 4,370.56% | 179.75% | -- |
| Cash from Financing | -94.33% | -93.71% | 351.24% | 700.81% | 195.80% |
| Foreign Exchange rate Adjustments | -78.47% | -83.43% | -103.43% | 0.41% | 202.90% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -195.09% | -191.99% | 1,500.28% | 114.71% | 482.30% |